Summary We investigated the ability of high concentrations of oestradiol to reverse the growth inhibitory action of tamoxifen on MCF-7 breast cancer cells in vivo. Tamoxifen inhibits the oestradiol stimulated growth of MCF-7 cells in athymic mice. Using a sustained release preparation of tamoxifen we consistently achieved serum concentrations of the drug in the 40 to 50 ng ml ' range and much higher levels in tissues. These serum levels are sufficient to inhibit the oestrogen stimulated growth of MCF-7 tumours exposed to physiologic (i.e. 300-600pgml-' serum oestradiol concentrations). However, by administering dosages that increase serum oestradiol concentrations to 900-2000 pg ml ', mimicking the increase often observed clinically in premenopausal women taking tamoxifen, we show that the growth inhibitory action of tamoxifen can be partially reversed. Serum tamoxifen levels were elevated to nearly 400 ng ml' by injecting 1 mg day-' tamoxifen (IP 3 x weekly); this dosage was more effective at inhibiting oestradiol stimulated tumour growth than subcutaneous tamoxifen capsules alone. Our data suggest that at low serum levels tamoxifen may not act optimally. There may be a need to monitor tamoxifen levels in premenopausal patients to ensure that they are high enough not to be overcome by a tamoxifen induced increase in ovarian steroidogenesis.
Tamoxifen, a non-steroidal antioestrogen, is the first line antihormonal therapy for breast cancer. Tamoxifen was originally introduced to treat advanced breast cancer in postmenopausal patients (Cole et al., 1971) , however the drug has proved to be effective in premenopausal patients as well (Buchanan et al., 1986; Ingle et al., 1986; Manni & Pearson, 1980; Sawka et al., 1986) . Recently tamoxifen has been evaluated as an adjuvant therapy in premenopausal women with either node positive (CRC Adjuvant Breast Trial Working Party, 1988; Nolvadex Adjuvant Trial Organization, 1988) or node negative disease (Breast Cancer Trials Committee, Scottish Cancer Trials Office, 1987; CRC Adjuvant Breast Trial Working Party, 1988; Fisher et al., 1989 ). An early analysis of the clinical trials data demonstrates an increase in disease free survival in those women receiving the antioestrogen. Indeed the use of tamoxifen is being extended to treat normal premenopausal women to evaluate whether an antioestrogen can prevent breast cancer (Powles et al., 1990) . However, the question can be asked whether antioestrogen therapy in premenopausal women is an optimal strategy. Tamoxifen is known to cause an elevation in ovarian steroidogenesis whether given in a short course (Groom & Griffiths, 1976; Senior et al., 1978) or as continuous therapy Jordan et al., 1991; Manni et al., 1979; Sherman et al., 1979) . Clearly, if tamoxifen is a competitive inhibitor of oestrogen action through the oestrogen receptor, then an increase in oestrogen levels might reverse the antitumour action of tamoxifen. We have addressed this question in a laboratory model. Tamoxifen inhibits the oestrogen-stimulated growth of tumours derived from the MCF-7 breast cancer cell line that have been inoculated into athymic mice (Gottardis et al., 1988) . We have now evaluated the relative ability of oestradiol and tamoxifen to control the growth of MCF-7 tumour cells in vivo. The significance of our findings is discussed in its clinical context.
Materials and methods
Tumours MCF-7 breast tumours were maintained as serially passaged solid tumours in ovariectomised athymic nude mice (HarlanSprague Dawley, Madison, WI), bearing 1.0 cm oestradiol capsules (described below). Tumours were routinely passaged by removing a > 1.0 cm diameter tumour from an oestradiol treated animal, trimming away all fat, skin, and necrotic tissue, and mincing the remaining viable tissue into pieces of approximately 1 mm3 in a bath of cold CMF-HBSS. Tumour pieces were then implanted into the thoracic mammary fat pads (1/side) of 4 to 5 week old athymic mice by using a 13 gauge trocar. At the time of tumour transplantation, all animals were also implanted subcutaneously with a 1.0 cm Silastic capsule containing 17P-oestradiol (described below).
Tumour measurements were performed weekly using calipers. Tumour cross sectional areas were calculated using the formula:
(length/2 x width/2) x 1 After 5 weeks of oestrogen treatment, tumours had reached an average size of 0.5 cm2. Animals were then randomised into six groups, and the oestradiol capsules were removed. All of the animals in each group then received one of the following treatments: a 1.0cm oestradiol capsule, a 2.0cm tamoxifen capsule, or a 2.0 cm tamoxifen capsule plus either a 1.7 mg oestradial pellet, or a 2.0 cm, 1.0 cm or 0.5 cm oestradiol capsule. Tumour cross sectional areas were recorded for each animal, means for each time point were calculated and then standardised to be expressed as a percentage of the tumour area at the outset of treatment. Standard errors were calculated from these standardised tumour areas.
In another experiment athymic mice (18) bitransplanted with MCF-7 tumours were treated with oestradiol (1 cm silastic capsule) until the tumour areas were approximately 0.6 cm2. Animals were divided into three groups of six mice: oestradiol alone, oestradiol plus a 2 cm tamoxifen implant or oestradiol, tamoxifen (2 cm capsule) and tamoxifen 1 mg IP 3 x per week (MWF).
Tumours were measured for 4 weeks, after which animals were sacrificed and tissues were taken for determination of tamoxifen. Oestrogen and progesterone receptors were determined by immunoassay using ER-EIA and PR-EIA kits (Abbot Laboratories, Chicago, IL Oestradiol and tamoxifen measurements Circulating 17p-oestradiol and tamoxifen levels were measures as previously described Langan Fahey et al., 1990) in serum samples taken from tumour bearing mice. Blood samples were obtained by bleeding from the eye orbit under light ether anaesthesia or at autopsy. After clotting overnight, samples were centrifuged at 2,000 g; serum was removed and stored at -20C until analysis.
Tamoxifen measurements in tissues were made using normal phase HPLC with fluorescent detection of the parent compound and metabolites as previously described (Robinson et al., 1991) .
Statistical analyses
All statistical calculations were performed using Minitab version 6.1 (Minitab, Inc., State College, PA) on an IBM PS/2 model 50Z or Tandy 3000 HD personal computer.
Results
Serum and tissue levels of tamoxifen in athymic mice during treatment with a sustained release silastic capsule In order to assess the efficacy of our sustained release preparation of tamoxifen, non-tumour bearing athymic mice were implanted with 2 cm tamoxifen capsules. At 2 week intervals beginning 2 weeks after capsule implantation serum specimens were obtained by drawing blood from the eye orbit of a random sample of mice; a subset of the mice were sacrificed and liver, uterus and muscle samples were collected for analysis of tamoxifen concentration.
As Figure la shows, serum tamoxifen levels did not change significantly, remaining around 30-40 ng ml-l (0.08-0.11 tAM) for the duration of treatment. Although a slight downward trend was evident towards the end of the experiment, none of the values were significantly different from each other. Figure lb shows the concentrations of tamoxifen in muscle, liver and uterine tissue samples taken during the course of the experiment. Tamoxifen levels in uterus and muscle remained fairly constant, showing slight decreases over time, possibly as drug levels in the capsules were gradually depleted. Mean tamoxifen levels in liver tissue, although fairly constant over time, showed much greater variability at each time point than any of the other tissues examined. This may be due to inter-animal variation in hepatic metabolic ability, or variability in the efficiency of extraction of drug from the lipid rich hepatic tissue. However, the internal enclomiphene control used in the tamoxifen assay makes the latter possibility relatively unlikely. Uterine wet weights were also measured in all test animals at the end of the experiment. Only the highest dose of oestradiol administered could partially reverse the inhibition of uterine growth by tamoxifen (Figure 3) . The antioestrogenic action of sustained release preparations of tamoxifen in the mouse uterus has previously been noted .
Oestradiol and tamoxifen concentrations in the serum and various tissues of experimental animals In animals receiving high dose injections, detectable levels of the metabolites, 4-hydroxytamoxifen and N-desmethyl tamoxifen (N-des) were detectable (Table II) Figure 5 . Although administration of tamoxifen capsules alone was sufficient to block further increases in tumour size, even greater inhibtion, i.e., a reduction in tumour area, was achieved by the administration of a high dose of tamoxifen. Figure 6 shows the amounts of oestrogen and progesterone receptors measured in the tumours in this experiment. It is apparent that though tamoxifen blocked the oestradiol induced increase of progesterone receptor in tumour cells in a dose dependent fashion, it also induced a dose dependent increase in oestrogen receptor levels in these tumours.
Discussion
The aim of these experiments was to determine the effectiveness of tamoxifen to control the growth of hormone responsive MCF-7 tumours grown in athymic mice under high and low oestrogen environments.
We used a sustained release method (Robinson & Jordan, 1989) to treat tumour bearing athymic mice with tamoxifen. The level of oestradiol we selected was targeted to be within the range normally observed in premenopausal patients during tamoxifen therapy (500-900 pg ml-'). Tamoxifen controlled oestradiol stimulated growth; a result that parallels clinical experience (Breast Cancer Trials Committee, Scottish Cancer Trials Office, 1989; Buchanan et al., 1986; CRC Adjuvant Breast Trial Working Party, 1988; Fisher et al., 1989; Ingle et al., 1986; Manni & Pearson, 1980; Nolvadex Adjuvant Trial Organization, 1988; Sawka et al., 1986) .
Although the action of tamoxifen was reversed with increasing circulating concentrations of oestradiol, the levels required appeared to be at the top of the range observed clinically in premenopausal women during tamoxifen therapy (Groom & Griffiths, 1976; Jordan et al., 1987; Jordan et al., 1991; Manni et al., 1979; Senior et al., 1978; Sherman et al., 1979) . Nevertheless the efficacy of tamoxifen seemed to be optimal in a low oestrogen environment. Indeed it has been suggested (Sawka et al., 1986 ) that ovarian steroids can reverse the action of tamoxifen since some patients who respond and then fail tamoxifen treatment can subsequently Figure 6 Oestrogen and progesterone receptor levels (± s.e.m.) in tumours from animals treated with either oestradiol (E2) alone, E2 plus a tamoxifen capsule, or E2 plus both a tamoxifen capsule and injections (1 mg IP 3 x weekly). Shaded bars -oestrogen receptor, striped bars -progesterone receptor. Five tumours were assayed for the E2 group, 11 for the tamoxifen capsule group alone, and eight for the high dose tamoxifen group. respond to oophorectomy.
Serum levels of tamoxifen achieved by our sustained release method (approximately 40 ng ml-') were at the low end of the range that we observe in patients during long term adjuvant therapy with tamoxifen (Langan-Fahey et al., 1990) . However, even at these levels, extremely high serum concentrations of oestradiol were required to cause tumour growth (Table I and Figure 2 ). It was encouraging to find that even low circulating concentrations of tamoxifen were effective at inhibiting tumour growth in the presence of concentrations of oestradiol in excess of that observed in most premenopausal women receiving tamoxifen, and that an increased dose of tamoxifen was even more effective at inhibiting tumour growth ( Figure 5 ). These principles may translate directly to the clinic. Perhaps premenopausal women taking tamoxifen should be monitored to ensure that they have circulating levels of tamoxifen in the 150-200 ng ml1 range -levels we have shown to be readily achievable (Langan Fahey et al., 1990) . If tamoxifen levels in this range can be maintained, administration of an LHRH agonist (Robertson et al., 1989; Walker et al., 1989) or oophorectomy in order to lower serum oestradiol levels may be unnecessary. It was interesting to observe that high concentrations of tamoxifen were present in the tumour compared to the serum. Tissues might be expected to accumulate tamoxifen because the triphenylethylenes are highly (>98%) protein bound. Unfortunately it is not possible to establish the proportion of the antioestrogen that is bioavailable. Nevertheless, the surrounding tissue could act as a drug depot for the target site. We noted that tamoxifen levels in the uterine tissue of animals treated with the three highest doses of oestrogen were significantly lower than levels seen in animals receiving tamoxifen alone. It is unlikely that this difference is due to competition for binding to the oestrogen receptor, as the receptor is present only in femtomolar concentrations in the tissue; consequently, changes in tissue sequestration due only to the elimination of tamoxifen binding to the oestrogen receptor could not be detected by our assay. It may be that oestradiol causes a down-regulation of uterine antioestrogen binding sites (Murphy & Sutherland, 1981) , or otherwise interferes with uterine retention of tamoxifen.
Tamoxifen is extensively metabolised in patients (Adam et al., 1979; Daniel et al., 1981) to a principal metabolite Ndesmethyltamoxifen and a minor metabolite 4-hydroxytamoxifen which has high affinity for the oestrogen receptor (Jordan et al., 1977) . The subcutaneous sustained release preparation of tamoxifen does not produce the same metabolite profile as that seen in patients. In fact tamoxifen was the major triphenylethylene detected at a circulating level of about 40 ng ml-' in all groups treated with tamoxifen capsules. Serum metabolites were detectable at only very low levels, and were not reliably detectable in tissues at all. In animals receiving high dose injections, the metabolites are detectable, as shown in Table II , but at a lower ratio to the parent compound that we have previously demonstrated (Robinson et al., 1991) . This may be due to differences in the method of drug administration, since in our previous paper, the animals were dosed orally, whereas in these experiments tamoxifen was administered intraperitoneally. A trend towards lower serum oestradiol levels in animals treated with tamoxifen compared to those in control mice is apparent (Table II) , but these differences did not reach statistical significance at the P<0.05 level.
Low circulating concentrations (-40 ng ml') of tamoxifen inhibited MCF-7 tumour growth in a high oestrogen environment (Figures 3 and 6 ) and caused an antiestrogenic change in the tumour steroid receptor concentrations. Tamoxifen decreased the concentration of progesterone receptor whilst causing an increase in the concentration of oestrogen receptors. Oestrogen withdrawal caused a similar increase in oestrogen receptors and decrease in progesterone receptors in MCF-7 cells in vitro (Welshons & Jordan, 1987) . Although tamoxifen is known to increase progesterone receptors in some target tissues in vivo and tumour cells in vitro (Campen et al., 1985; Horwitz et al., 1978; Koseki et al., 1978) tamoxifen prevented oestrogen induced increases in MCF-7 tumour progesterone receptor in vivo.
It has been previously reported that tamoxifen induces ovarian steroidogenesis in premenopausal women. In this report we have shown that increasing circulating levels of oestradiol are capable of reversing the growth inhibitory effect tamoxifen has on oestrogen responsive tissues, i.e. tumour and uterine tissue in vivo. We believe that although the high circulating levels of oestradiol required to interfere with the effects of tamoxifen on breast tumour tissue in the laboratory are at the high end of the range seen clinically, these results should nevertheless be viewed with some interest by the clinical community as they indicate a need to be aware of the actual serum tamoxifen levels achieved in their patients rather than only the dose administered.
